The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patient-reported outcomes (PROs) in the randomized, phase III IMpower110 study of atezolizumab (atezo) vs chemotherapy in 1L metastatic NSCLC.
 
Filippo de Marinis
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Pfizer; Roche/Genentech
 
Giuseppe Giaccone
Consulting or Advisory Role - ARMO BioSciences; BerGenBio; CStone Pharmaceuticals
Research Funding - Bayer; Incyte; Lilly; MedImmune (Inst)
 
Roy S. Herbst
Leadership - Junshi Pharmaceuticals
Consulting or Advisory Role - Abbvie; ARMO Biosciences; AstraZeneca; Biodesix; Bolt Biotherapeutics; Bristol-Myers Squibb; EMD Serono; Genentech/Roche; Genmab; Halozyme; Heat Biologics; I-Mab; Immunocore; Infinity Pharmaceuticals; Junshi Pharmaceuticals; Lilly; Loxo; Merck; Midas Health Analytics; Mirati Therapeutics; Nektar; Neon Therapeutics; NextCure; Novartis; Pfizer; Sanofi; Seagen; Shire; Spectrum Pharmaceuticals; Symphogen; Takeda; TESARO; Tocagen
Research Funding - AstraZeneca; Genentech/Roche; Lilly; Merck
 
Cristina-Marinela Oprean
Consulting or Advisory Role - Lilly; Merck
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Johnson & Johnson; Lilly; Merck; MSD; Novartis; Pfizer; Roche; Sandoz; Teva
Research Funding - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Genentech; Glycotope GmbH; Mylan; Samsung
Expert Testimony - Roche
 
Aleksandra Szczesna
No Relationships to Disclose
 
Ioannis Boukovinas
Employment - Pierre Fabre (I)
Honoraria - AstraZeneca; Bristol-Myers Squibb; LEO Pharma; Merck; MSD; Novartis; Pfizer; Roche; SERVIER
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genesis Pharma; Ipsen; LEO Pharma; MSD; Novartis; Roche; Sanofi
Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Regeneron; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; MSD; Pfizer; Roche; Servier
 
Lucia Bonomi
Consulting or Advisory Role - Janssen Oncology
Travel, Accommodations, Expenses - Ipsen; Janssen Oncology; Novartis; Pfizer
 
Young-Chul Kim
Honoraria - AstraZeneca; Bristol-Myers Squibb; Ono Pharmaceutical; Roche; Takeda
Research Funding - AstraZeneca; Roche
 
Yvonne J. Summers
Honoraria - AstraZeneca; Bristol-Myers Squibb; Takeda
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; Novartis; Pfizer
Speakers' Bureau - AstraZeneca; Takeda
Travel, Accommodations, Expenses - MSD; Roche; Takeda
 
Takayasu Kurata
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD Oncology; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst)
 
Kimberly Mayumi Komatsubara
Employment - Genentech
 
Megan Chen
Employment - Genentech
 
Yu Deng
Employment - Genentech; Genentech
Stock and Other Ownership Interests - Genentech
Travel, Accommodations, Expenses - Genentech
 
Hiroshi Kuriki
Employment - Chugai Pharma; Genentech; Genentech
Stock and Other Ownership Interests - Chugai Pharma
 
Simonetta Mocci
Employment - Roche/Genentech
 
See Phan
Employment - Genentech
 
Jacek Jassem
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Pfizer; Takeda
Speakers' Bureau - AstraZeneca; Pfizer; Roche
Travel, Accommodations, Expenses - Pfizer; Roche
 
David R. Spigel
Leadership - TriStar Centennial Medical Center
Consulting or Advisory Role - Aptitude Health (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Dracen (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Iksuda Therapeutics (Inst); Illumina (Inst); Merck (Inst); Molecular Templates (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Seagen (Inst); Takeda (Inst); TRIPTYCH Health Partners (Inst); TRM Oncology (Inst); Williams and Connolly (Inst)
Research Funding - Aeglea Biotherapeutics (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BIND Therapeutics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); GRAIL (Inst); ImClone Systems (Inst); Immunogen (Inst); Ipsen (Inst); Janssen Oncology (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Molecular Partners (Inst); Nektar (Inst); Neon Therapeutics (Inst); Novartis (Inst); Takeda (Inst); Transgene (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Genentech; GlaxoSmithKline; Janssen Oncology; Merck; Novartis; Pfizer; Seagen; Spectrum Pharmaceuticals; Takeda